News Sentiment

BYSI sentiment intelligence

BeyondSpring Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 52 Balanced news tone 47 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 1.44 Week of 10 Jul 2026
Weighted tone 52/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

82/100 classification confidence.

Company focus 39

directly relevant articles

Source quality 0

high-authority source matches

Trend context Trend inactive

-23.0% over one week, -8.3% over four weeks, trend inactive, and near fair-value range.

Latest direct headline Negative

BeyondSpring (BYSI) Q1 2026 Earnings: EPS Loss of -$0.05 Amid No Revenue and Stock Decline - Guidance vs Actual

Market Reaction

Price moving ahead of tone

61/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 82/100 classification
One-week reaction -23.0% Price reacting lower
Trend fit Trend inactive -8.3% over four weeks
Fair value -17.0% Near fair-value range

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 9
Neutral 28
Negative 10

Relevance

Why the article matched

Direct first
Direct company coverage 39
Industry context 8
Sector context 0

Sources

Coverage mix

Publishers
TradingKey 7
Stock Titan 6
TradingView 6
Market source 5
GlobeNewswire 5
DonanımHaber 4
simplywall.st 2
Investing.com Nigeria 1

Event Lens

What the news is about

Classified themes
Market update 28
Earnings 16
Regulatory and legal 1
Deals and strategy 1
Analyst action 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 31-47 of 47
The Manila Times Direct company coverage

BeyondSpring Presents the Latest Update of a Phase 2 Study Demonstrating Durable Clinical Benefit of Pembrolizumab Plus Plinabulin/Docetaxel in Metastatic NSCLC After Progression on First-Line Immune Checkpoint Inhibitor Therapy at ASCO 2026

BeyondSpring announced updated efficacy and safety data from a Phase 2 study of pembrolizumab plus Plinabulin and docetaxel in metastatic NSCLC patients who progressed after first-line immune checkpoint inhibitor therapy. The study, presented at ASCO 2026, demonstrated durable cl

Tone
Positive 71/100
Event
Market update
Published
03 Jun 2026 10:39
Source
The Manila Times
GlobeNewswire Direct company coverage

BeyondSpring Presents the Latest Update of a Phase 2 Study

BeyondSpring Inc. announced updated efficacy and safety data from an investigator-initiated Phase 2 study of pembrolizumab plus Plinabulin and docetaxel for metastatic non-small cell lung cancer (NSCLC) patients who progressed after first-line immune checkpoint inhibitor therapy.

Tone
Positive 73/100
Event
Market update
Published
02 Jun 2026 10:40
Source
GlobeNewswire
GlobeNewswire Direct company coverage

BeyondSpring Announces Poster Presentation at 2026 ASCO Annual Meeting

BeyondSpring Inc. announced an upcoming poster presentation at the 2026 ASCO Annual Meeting. The presentation will detail Study 303, an investigator-initiated Phase 2 study supported by Merck and BeyondSpring, focusing on a triple combination therapy for metastatic non-small cell

Tone
Positive 67/100
Event
Market update
Published
18 May 2026 11:10
Source
GlobeNewswire